Amryt Pharma PLC Director/PDMR Shareholding (1189C)

TIDMAMYT

RNS Number : 1189C

Amryt Pharma PLC

10 April 2017

10 April 2017

AIM: AMYT

ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

Director Share Purchase

Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, announces that it has been notified that Markus Ziener, Non-Executive Director, has purchased 100,000 ordinary shares of 1p each ("Ordinary Shares") at a price of 21.5p per Ordinary Share.

Following this transaction, Mr Ziener holds 100,000 Ordinary Shares, representing 0.05% of the Company's issued share capital (excluding treasury shares). Mr Ziener is the Executive Managing Director of Software AG Stiftung, a 20.9% shareholder in Amryt.

Full details as required under the Market Abuse Regulation are set out below.

Notification of Transactions of Directors / Persons Discharging Managerial Responsibility and Connected Persons

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  -------------------------------------------------------- 
 a)   Name                        Markus Ziener 
---  -------------------------  ----------------------------- 
 2    Reason for the notification 
---  -------------------------------------------------------- 
 a)   Position/status            Non-Executive Director 
---  -------------------------  ----------------------------- 
 b)   Initial notification       Initial notification 
       /Amendment 
---  -------------------------  ----------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  -------------------------------------------------------- 
 a)   Name                       Amryt Pharma plc 
---  -------------------------  ----------------------------- 
 b)   LEI                        213800BOS8WAJO2BEQ38 
---  -------------------------  ----------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  -------------------------------------------------------- 
 a)   Description of 
       the financial               Ordinary shares of 1p each 
       instrument, type            in Amryt Pharma plc 
       of instrument 
                                   GB00BDD1LS57 
       Identification 
       code 
---  -------------------------  ----------------------------- 
 b)   Nature of the              Purchase of shares 
       transaction 
---  -------------------------  ----------------------------- 
 c)   Price(s) and volume(s)       Price(s)   Volume(s) 
                                   ---------  ---------- 
                                    21.5p      100,000 
                                   ---------  ---------- 
---  -------------------------  ----------------------------- 
 d)   Aggregated information 
       - Aggregated volume 
       - Price                     N/A (single transaction) 
---  -------------------------  ----------------------------- 
 e)   Date of the transaction    30/03/17 
---  -------------------------  ----------------------------- 
 f)   Place of the transaction   London Stock Exchange, AIM 
                                  Market (XLON) 
---  -------------------------  ----------------------------- 
 

Enquiries:

 
 Amryt Pharma plc                 C/o KTZ Communications 
 Joe Wiley, CEO 
  Rory Nealon, CFO/COO 
                                  +44 (0) 20 
 Shore Capital                     7408 4090 
 Nomad and Joint Broker 
 Bidhi Bhoma, Edward Mansfield 
                                  +353 (1) 679 
 Davy                              6363 
 ESM Adviser and Joint 
  Broker 
 John Frain, Anthony Farrell 
                                  +44 (0) 20 
 Stifel                            7710 7600 
 Joint Broker 
 Jonathan Senior, Ben 
  Maddison 
                                  +44 (0) 20 
 KTZ Communications                3178 6378 
 Katie Tzouliadis, Emma 
  Pearson 
 

About Amryt Pharma plc - see www.amrytpharma.com

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

The Company recently acquired an exclusive licence to sell LOJUXTA (lomitapide), across the EU and other territories including the Middle East, North Africa, Turkey and Israel. LOJUXTA is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia.

Amryt's product, AP101 (Episalvan), received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to develop AP101 (Episalvan) as a new treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. The Company recently received regulatory clarity from the FDA and the EMA regarding its Phase 3 study of AP101 (Episalvan) in EB, which has been granted US and EU orphan drug designation, and the first study site was initiated at the end of March 2017. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. AP102 was recently granted orphan designation in the US in acromegaly by the FDA.

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKKDDABKDCQD

(END) Dow Jones Newswires

April 10, 2017 12:21 ET (16:21 GMT)